Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan)
- PMID: 2824522
- PMCID: PMC12248321
- DOI: 10.1007/BF00390866
Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan)
Abstract
A total of 190 patients with unresectable non-small cell lung cancer (NSCLC) were analyzed retrospectively using eight pretreatment and three treatment-related prognostic factors in terms of influence on survival. All the patients received chemotherapy with or without chest irradiation, according to the protocol of phase II or phase III trials of the National Cancer Center Hospital Tokyo between April 1980 and December 1985. The eight pretreatment factors selected were performance status, sex, stage, age, histology, and metastasis to brain, bone or, liver. Three treatment-related factors were radiation therapy to the primary site, response to chemotherapy, and treatment period, before or after clinical administration of cis-diamminedichloroplatinum (II) (CDDP). Of the 190 patients, 71 (37.4%) were alive for more than 1 year, but only 17 patients (8.9%) survived 2 years after the initiation of chemotherapy. By univariate analysis, performance status 0-1, female, no metastasis to bone or liver, response to chemotherapy, and treatment period after CDDP were considered to be favorable prognostic factors. By multiregression analysis, performance status, sex, and treatment period after CDDP proved to be important factors for long-term survival. Consideration of these prognostic factors could enable the results of chemotherapy to be more accurately evaluated, and stratification of patients with advanced NSCLC based on performance status and sex before entry into a randomized controlled trial is recommended.
References
-
- Dhingra HM, Valdivieso M, Carr DT, Chiuten DF, Farha P, Murphy WK, Spitzer G, Umsawasdi T (1985) Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-123 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 3:176–183 - PubMed
-
- Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986) Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 4:702–709 - PubMed
-
- Glatstein E, Makuch RW (1984) Illusion and reality: practical pitfalls in interpreting clinical trials. J Clin Oncol 2:488–497 - PubMed
-
- Gralla RJ, Casper ES, Kelsen DP, Braun DW, Dukeman ME, Martini N, Young CW, Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95:414–420 - PubMed
-
- Klastersky J, Schuller JP, Weerts ND, Mairesse M, Libert P, Rocmans P, Michel J, Ferremans W (1983) Combination chemotherapy with cisplatin, etoposide and vindesine in non-small cell carcinoma: a clinical trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 67:727–730 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous